Is convalescent plasma therapy effective for COVID-19? Our initial experience at tertiary care center
| Autor: | Neha Jayant Hurkat, Venkat Ramulu, Srinivas Gurram |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Global Journal of Transfusion Medicine, Vol 6, Iss 1, Pp 26-32 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2468-8398 2455-8893 |
| DOI: | 10.4103/GJTM.GJTM_111_20 |
| Popis: | Background and Objectives: Previous studies suggest that convalescent plasma (CP) may be effective in improving survival rates in COVID-19 patients. But still there is uncertainty regarding effectiveness of CP in improving mortality or clinical improvement in COVID-19 patient as randomized studies were short of statistical significance. We aim to report our initial experience with CP transfusions for COVID 19 patients at a tertiary care set up with regard to its efficacy and safety in patients at various stages of disease. Methods: This is an observational study which includes 324 patients who have received convalescent plasma from 1st July to 31st August 2020 in a tertiary care set up. The outcome of the study was measured by recovery of the patient and discharge from hospital in stable condition. Recovery was defined as no fever for 3 consecutive days, respiratory rate and oxygen saturation returning to normal at room air and patient being hemodynamically stable. Results: The overall recovery was attained in 249/324 patients (76.9%) and 75/324 patients (23.1%) died in hospital. In moderate disease patients the recovery rate was found to be 96.1%. In Severe disease patients, 38.8% recovered and in critically ill patients, 23.4% recovered. 80.6% patients recovered who received plasma within 5 days of hospitalization where as only 67.4% patients recovered who received plasma after 5 days of hospitalisation indicating earlier administration of CP in disease course has better outcomes. SARS-CoV 2 IgG ab levels of CP units correlated with outcome. The recovery was significantly higher in patients who received CP with higher IgG values (>12) as compared to patients who received CP with lower IgG values ( |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|